AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04730700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation with MEE
Description: RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.
Study NCT04730700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Medical Management
Description: Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.
Study NCT03829540 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD4CAR
Description: CD4CAR cells transduced with a lentiviral vector to express the single-chain variable fragment (scFv) nucleotide sequence of the anti-CD4 molecule derived from humanized monoclonal ibalizumab and the intracellular domains of CD28 and 4-1BB co-activators fused to the CD3ζ T-cell activation signaling domain administered by IV infusions as a single dose
Study NCT02923726 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm 1 (ATP+Shock)
Description: Subjects will be randomized and device programmed to the respective arm.
Study NCT02923726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm 2 (shock only)
Description: Subjects will be randomized and device programmed to the respective arm.
Study NCT01300754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose Injection
Description: 12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
Study NCT01300754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Injection
Description: 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
Study NCT01300754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
Study NCT04442295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-001 - Single Ascending Doses
Description: Experimental : Single Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Four dose levels will be evaluated ( 10mg, 20mg,30mg, 45mg and 70mg ).
Study NCT04442295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STK-001 - Multiple Ascending Doses
Description: Experimental : Multiple Ascending Doses - STK-001 drug product is an antisense oligonucleotide administered as an intrathecal injection. Three dose levels will be evaluated ( 20mg,30mg and 45mg ).
Study NCT01122238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):~Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks.
Study NCT01122238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Gum
Description: If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):~Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks.
Study NCT01170559 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Loop Recorder
Study NCT02437071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
Study NCT01122238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking.
Study NCT01122238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Reduction
Description: Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
Study NCT01122238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: No Intervention
Study NCT01122238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch + Nicotine Gum
Description: If randomized to both the Nicotine Patch and the Nicotine Gum conditions:~Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks.
Study NCT02731586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic Mesenchymal stem cells
Description: Allogenic mesenchymal stem cells are introduced during placement of dental implants.
Study NCT03802006 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound assessment of gastric content
Description: Ultrasound assessment of gastric body is performed
Study NCT04475978 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVUS-guide DCB PTCA
Description: IVUS-guide DCB PTCA
Study NCT04475978 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Angio-guide DCB PTCA
Description: Angio-guide DCB PTCA
Study NCT03331315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT03331315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Study NCT02437071 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT02437071 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Study NCT00682890 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo birth control pill daily
Study NCT00682890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 2000 mg per day for 3 months daily birth control pill
Study NCT01323647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PoliorixTM
Description: Single dose, intramuscular administration
Study NCT01323647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix+Hib
Description: Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
Study NCT01323647 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix+Hib
Description: Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
Study NCT01426867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Study NCT01426867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brinzolamide ophthalmic suspension, 1%
Study NCT01426867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine tartrate ophthalmic solution, 0.2%
Study NCT01948726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation with simultaneous integrated boost
Study NCT02199704 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self Directed Positive Parenting Program
Description: Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders \& Turner, 1999) and up to ten sessions of support. This is a case series study.
Study NCT02923687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
Study NCT02923687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
Study NCT01358487 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help course plus live follow-up if needed
Description: In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
Study NCT01358487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online + incentives Follow-up Group
Description: This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
Study NCT03536754 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)
Study NCT03536754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.
Study NCT03536754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.
Study NCT03536754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.
Study NCT02801968 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tap block
Study NCT02801968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intravenous analgesia
Study NCT02801968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intravenous analgesia
Study NCT00252577 — intervention group
Intervention type: DRUG
Intervention: Lithium treatment
Description: Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
Study NCT03099746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INVOLVE
Description: Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
Study NCT03099746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational Support
Description: Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
Study NCT03149679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study NCT03817359 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol mixture
Description: Participants receive total intravenous anesthesia with remifentanil-propofol mixture by single TCI pump in intervention group. All TCI target concentration adjustments or extra bolus of propofol or remifentanil during operation were based on BIS and ANI monitor.
Study NCT03099746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
Study NCT03099499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
Study NCT02031692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate
Description: The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
Study NCT04312217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical clowning
Description: Medical clowning
Study NCT01759576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
Study NCT04206930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art Therapy
Description: 1 session of 2 hours per week in a closed group for 10 weeks
Study NCT04208945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: 500000 units of inhaled colistin three times daily for 10 days
Study NCT00915252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:~During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).~During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy.
Study NCT01670760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero-heat-flux thermometry
Description: The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
Study NCT02450799 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acrylic IOL
Description: Acrylic IOL for long-term implantation in the cataract patient
Study NCT02450799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone IOL
Description: Silicone IOL for long-term implantation in the cataract patient
Study NCT02450799 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PMMA IOL
Description: Polymethylmethacrylate IOL for long-term implantation in the cataract patient
Study NCT04612959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosexual care
Description: The psychosexual caring program includes interventions to promote body awareness, the meaning of sexuality, and marital relationships by gaining communication skills, sexual communication, body knowledge, information about sexual health, and its dimensions.The psychosexual caring program includes psycho-education and sexual counseling.
Study NCT01312012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiviral therapy
Description: 100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level > 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
Study NCT00601094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-adenovirus CCL21 vaccine
Description: Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
Study NCT02650882 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device POWERbreathe
Study NCT02650882 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Device POWERbreathe
Study NCT04773197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues (BtB)
Description: Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
Study NCT04773197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beating the Blues (BtB)
Description: Beating the Blues (BtB) is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
Study NCT00915252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine
Description: Induction therapy:~Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7~Consolidation therapy:~AraC 1g/m² twice a day on day 1,3,5
Study NCT01969136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: EVP-6124
Study NCT01969136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02351817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test A
Description: Ostomy appliance
Study NCT02351817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test B
Description: Ostomy appliance
Study NCT04773197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Entertain Me Well (EMW)
Description: Entertain Me Well (EMW) is is a C-CBT intervention with 8 weekly sessions to be completed within 10 weeks.
Study NCT04773197 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
Study NCT04773197 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: A coach will spend approximately 5-10 minutes after each session with the patient to link the C-CBT content with patient's disease specific experiences and to motivate them to continue the program. They will also spend approximately 5 minutes between sessions to motivate a patient to complete assignments and to remind them about starting the next session on time.
Study NCT04782466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) Intervention
Description: The ATOMIC intervention consists of four primary components: one-on-one chats with a PA coach, informational posts, PA self-monitoring through an activity tracker and educational modules regarding different aspects of becoming PA delivered through the MS-specific PA app. An overarching goal of moving youth with MS towards meeting current Moderate to Vigorous Physical Activity (MVPA) recommendations will be used in addition to initial results from accelerometer monitoring and evaluation of current PA intentions to establish step goals, with planned weekly incremental increases (10% weekly to goal).
Study NCT04782466 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist attention-control
Description: For a period of 6-months, participants will receive the control conditions that involve contact from study personnel and a nutritional educational module to ensure equivalent social contact in both arms of the study. After the 6-months, participants will receive the same intervention as the intervention arm.
Study NCT03759951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DoIT-1
Description: A hybrid small-group (5-10 participants/session) training modality, that combines interval training, circuit-based resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management, health, performance and well-being. DoIT will be performed once per week on non-consecutive days for 12 months.